nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

28.01.2022 | Brief Report

Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants

verfasst von: Laurent Poirel, Mustafa Sadek, Ayda Kusaksizoglu, Patrice Nordmann

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Cefiderocol (FDC) and ceftazidime-avibactam (CZA) are among the latest generation of commercialized antibiotics against carbapenem-resistant Gram negatives. However, emergence of CZA resistance is being increasingly reported, involving different KPC variants in Enterobacterales. By analyzing two CZA-resistant KPC-3 clinical variants, KPC-41 and KPC-50, we showed that KPC-41, and to a lesser extent KPC-50, may also have an impact on susceptibility to FDC leading to a cross-resistance. This feature highlights that a susceptibility testing to FDC is mandatory prior any clinical use of FDC for treating infections due to KPC producers.

Munoz-Price LS, Poirel L, Bonomo RA et al (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13(9):785–796. https://doi.org/10.1016/S1473-3099(13)70190-7CrossRefPubMedPubMedCentral

Kazmierczak KM, Biedenbach DJ, Hackel M et al (2016) Global dissemination of bla_KPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam. Antimicrob Agents Chemother 60(8):4490–4500. https://doi.org/10.1128/AAC.00107-16CrossRefPubMedPubMedCentral

Zhanel GG, Lawson CD, Adam H et al (2013) Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73(2):159–177. https://doi.org/10.1007/s40265-013-0013-7CrossRefPubMed

Sharma R, Park TE, Moy S (2016) Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination for the treatment of resistant Gram-negative organisms. Clin Ther 38(3):431–444. https://doi.org/10.1016/j.clinthera.2016.01.018CrossRefPubMed

Barnes MD, Winkler ML, Taracila MA et al (2017) Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from β-lactamase protein engineering. MBio 8(5):e00528-e617. https://doi.org/10.1128/mBio.00528-17CrossRefPubMedPubMedCentral

Hemarajata P, Humphries RM (2019) Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2. J Antimicrob Chemother 74(5):1241–1243. https://doi.org/10.1093/jac/dkz026CrossRefPubMed

Di Pilato V, Aiezza N, Viaggi V et al (2020) KPC-53, a KPC-3 Variant of clinical origin associated with reduced susceptibility to ceftazidime-avibactam. Antimicrob Agents Chemother 65(1):e01429-e1520. https://doi.org/10.1128/AAC.01429-20CrossRefPubMedPubMedCentral

Livermore DM, Warner M, Jamrozy D et al (2015) In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 59(9):5324–5330. https://doi.org/10.1128/AAC.00678-15CrossRefPubMedPubMedCentral

Shields RK, Chen L, Cheng S et al (2017) Emergence of ceftazidime-avibactam resistance due to plasmid-borne bla_KPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61(3):e02097-e2116. https://doi.org/10.1128/AAC.02097-16CrossRefPubMedPubMedCentral

10.

Shields RK, Nguyen MH, Chen L et al (2018) Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother 62(5):e02497-e2517. https://doi.org/10.1128/AAC.02497-17CrossRefPubMedPubMedCentral

11.

Venditti C, Nisii C, D’Arezzo S et al (2019) Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in bla_KPC-3-harboring Klebsiella pneumoniae. Infect Drug Resist 12:1935–1940. https://doi.org/10.2147/IDR.S207993CrossRefPubMedPubMedCentral

12.

Mueller L, Masseron A, Prod’Hom G et al (2019) Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity. Antimicrob Agents Chemother 63(12):e01111-e1119. https://doi.org/10.1128/AAC.01111-19CrossRefPubMedCentral

13.

Poirel L, Vuillemin X, Juhas M et al (2020) KPC-50 confers resistance to ceftazidime-avibactam associated with reduced carbapenemase activity. Antimicrob Agents Chemother 64(8):e00321-e420. https://doi.org/10.1128/AAC.00321-20CrossRefPubMedPubMedCentral

14.

Findlay J, Poirel L, Juhas M, Nordmann P (2021) KPC-mediated resistance to ceftazidime-avibactam and collateral effects in Klebsiella pneumoniae. Antimicrob Agents Chemother 65(9):e0089021. https://doi.org/10.1128/AAC.00890-21CrossRefPubMed

15.

Kohira N, West J, Ito A et al (2015) In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 60(2):729–734. https://doi.org/10.1128/AAC.01695-15CrossRefPubMed

16.

Hackel MA, Tsuji M, Yamano Y et al (2018) In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother 62(2):e01968-e2017. https://doi.org/10.1128/AAC.01968-17CrossRefPubMedPubMedCentral

17.

Sato T, Yamawaki K (2019) Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis 69(Suppl 7):S538–S543. https://doi.org/10.1093/cid/ciz826CrossRefPubMedPubMedCentral

18.

Kohira N, Hackel MA, Ishioka Y et al (2020) Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J Glob Antimicrob Resist 22:738–741. https://doi.org/10.1016/j.jgar.2020.07.009CrossRefPubMed

19.

Poirel L, Sadek M, Nordmann P (2021) Contribution of PER-type and NDM-type β-lactamases to cefiderocol resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 65(10):e0087721. https://doi.org/10.1128/AAC.00877-21CrossRefPubMed

20.

Hobson CA, Cointe A, Jacquier H et al (2021) Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect. Clin Microbiol Infect 27(8):1172.e7-1172.e10. https://doi.org/10.1016/j.cmi.2021.04.016CrossRef

21.

EUCAST (2021) The European Committee on antimicrobial susceptibility testing breakpoint tables for interpretation of MICs and zone diameters, version v11.0. 2021.https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf.

22.

Poirel L, Ortiz de la Rosa JM, Richard A, Aires-de-Sousa M, Nordmann P (2019) CTX-M-33, a CTX-M-15 derivative conferring reduced susceptibility to carbapenems. Antimicrob Agents Chemother 63(12):e01515-e1519. https://doi.org/10.1128/AAC.01515-19CrossRefPubMedCentral

23.

Ito A, Sato T, Ota M et al (2017) In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother 62(1):e01454-e1517. https://doi.org/10.1128/AAC.01454-17CrossRefPubMedPubMedCentral

24.

Bianco G, Boattini M, Comini S et al (2021) In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects [published online ahead of print, 2021 Aug 31]. Eur J Clin Microbiol Infect Dis. https://doi.org/10.1007/s10096-021-04341-z

25.

Tiseo G, Falcone M, Leonildi A et al (2021) Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 Klebsiella pneumoniae-producing KPC-31, a D179Y variant of KPC-3. Open Forum Infect Dis 8(6):ofab141. https://doi.org/10.1093/ofid/ofab141

Titel: Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants
verfasst von: Laurent Poirel
Mustafa Sadek
Ayda Kusaksizoglu
Patrice Nordmann
Publikationsdatum: 28.01.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 4/2022
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-021-04397-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Pasteurella species bloodstream infections in Queensland, Australia, 2000–2019

Fosfomycin as a salvage therapy for treating urinary tract infections due to multidrug-resistant Escherichia coli

Protocatechuic acid protects mice from influenza A virus infection

Capnocytophaga zoonotic infections: a 10-year retrospective study (the French CANCAN study)

Mortality-associated factors of candidemia: a multi-center prospective cohort in Turkey

Rapid diagnostic test (Leptocheck-WB) for detection of acute leptospirosis: a meta-analysis of diagnostic accuracy

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin